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Abstract
Plasma cell dyscrasias are immunosecretory disorders that can lead to hematological malignancies such as Multiple
Myeloma (MM). MM accounts for 15% of all hematologic cancers, and those diagnosed with MM typically become severely
ill and have a low life expectancy. Monoclonal immunoglobulin Free Light Chains (FLC) are present in the serum and urine
of many patients with plasma cell diseases. The biological differences between monoclonal FLCs, produced under
malignant or benign dyscrasias, has not yet been characterized. In the present study, we show that endothelial and heart
muscle cell lines internalize kappa and lambda FLCs. After internalization, FLCs are rerouted in the extracellular space via
microvesicles and exosomes that can be re-internalized in contiguous cells. Only FLCs secreted from malignant B
Lymphocytes were carried in Hsp70, annexin V, and c-src positive vesicles. In both MM and AL Amyloidosis patients we
observed an increase in microvesicle and exosome production. Isolated serum vesicles from MM, AL Amyloidosis and
monoclonal gammopathy of undetermined significance (MGUS) patients contained FLCs. Furthermore MM and AL
amyloidosis vesicles were strongly positive for Hsp70, annexin V, and c-src compared to MGUS and control patients. These
are the first data implying that FLCs reroute via microvesicles in the blood stream, and also suggest a potential novel
mechanism of c-src activation in plasma cell dyscrasia.
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Introduction
Hematological malignancies may be a result of plasma cell
dyscrasia such as MGUS, or smouldering multiple myeloma
(SMM). MGUS can be diagnosed incidentally and can behave like
a benign, asymptomatic entity, or it can progress (1% per year) to
different hematologic malignancies such as multiple myeloma
(MM) [1,2]. The SMM asymptomatic plasma cell disorder carries
a higher risk of progression (10% in the first 5 years) compared
with MGUS [3]. Unfortunately, we currently lack reliable
biological markers that allow us to predict which MGUS or
SMM patient will progress to MM [4]. Improved detection
techniques, at the molecular level, could help in disease
management of patients diagnosed with MGUS, SMM, or MM.
B cell clones, either malignant or benign, normally produce
high amounts of monoclonal immunoglobulins (paraproteins).
Paraproteins are made up of intact immunoglobulins and either
single light chains or, more rarely, single heavy chains. Kappa or
lambda FLC have been long-considered a by-product of plasma
cells. However, recently published data indicate that serum FLCs
may account for some specific functions during immune response
[5]. Bradwell and co-workers developed an assay that can detect
only FLC in a milieu of free and bound LC [6]. The assay has now
been widely adopted in clinical practice and has revealed a clear
imbalance of the free kappa light chains versus free lambda light
chains in plasma cell dyscrasia. In fact, an abnormal FLC ratio [7–
9] has proven to be predictive for the progression of MGUS,
solitary plasmacytoma of bone, amyloidosis, MM, Waldenstrom’s
macroglobulinemia and SMM [10–12].
A subset of monoclonal FLCs possesses intrinsic pathogenicity,
which is a trigger factor of diseases such as AL amyloidosis and
light chain deposition disease (LCDD) [13,14]. Amyloidogenic
FLCs circulate through the vascular system and deposit as
insoluble fibrils, which leads to kidney, heart, and lung damage.
Renal damage is, in most cases, the earliest indication of systemic
involvement [15,16]. The cardiac involvement occurs in more
than 50% of AL amyloidosis patients and is a leading cause of
morbidity [17]. Paraproteins are thus able to induce different
tissue damage. However, the molecular mechanism related to the
clinical progression is not fully understood.
The first evidence of intracellular uptake of kappa and lambda
FLC was published 10 years ago [18]. To date, only the trafficking
pathways of FLCs in cardiac fibroblasts [19], and kidney epithelial
and mesangial cells [20] have been studied, together with the
function of FLCs in the tubulo-interstitial environment [21].
Receptor mediated endocytosis and metabolism of FLCs generate
an intra-renal pro-inflammatory environment that exacerbates
ongoing renal injury via src-Tyrosine Kinase (c-src), NF-kB
activation, and nuclear translocation of p65, H2O2, and MCP-1
production. Not all FLCs are able to activate the proximal tubule;
it has been hypothesized that this phenomenon involves the
physicochemical composition of FLCs [21,22]. The FLCs’
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mediated generation of pro-inflammatory environment in the
vascular bed has never been considered. But before acting in
specific tissues, FLCs must cross the endothelial layer. Growing
evidence suggests that microvesicles and exosomes play a major
role in intercellular communication. Several studies demonstrate
that exosomes can modulate immunoregulatory processes, set up
tumour escape mechanisms, and transfer physiological informa-
tion [23,24].
In the present study, we characterize the internalization rate of
different FLCs in endothelial and myocardial cells. We show that
endothelial and heart muscle cell lines are both able to efficiently
internalize kappa and lambda FLCs. After internalization, FLCs
are rerouted in the extracellular space via microvesicles exosomes.
We processed serum samples from MM, AL Amyloidosis, MGUS,
and healthy patients as the control. We saw a significant increase
in microvesicle exosome production only in MM and AL
Amyloidosis patients. Furthermore, the serum vesicles containing
FLCs from MM and AL Amyloidosis patients were strongly
positive for Hsp70 and c-src compared to MGUS and control
patients. Our data show a FLCs rerouting process via microves-
icles and exosomes, and also suggest a potential novel mechanism
of c-src activation and function. Finally, we show a new potential
diagnostic target to evaluate the FLCs’ pathogenicity.
Methods
Ethics Statement
Serum samples from patients were collected from the Labora-
tory of Biochemical Chemistry, Azienda Ospedaliera Spedali
Civili of Brescia (AOSCB). Waste serum samples, derived from
routine analysis, were selected for diagnosis and paraprotein
production, coded, anonymized and frozen at –80uC: monoclonal
components were detected by high-resolution agarose gel electro-
phoresis/immunofixation (Interlab). Kappa/Lambda ratio of
serum FLCs concentration was measured by particle enhanced
nephelometry (Freelite assay, The Binding Site) on a Behring BNII
Nephelometer (Dade Behring). The institutional review board of
Azienda Ospedaliera Spedali Civili of Brescia approved the study
in adherence with the Declaration of Helsinki. All patients
provided their written consent to participate in this study. All
traceable identifiers were removed before analysis to protect
patient confidentiality, all samples were analyzed anonymously.
Cell Culture and Treatment
N Cell Culture: HeLa (ATCC CCL-2) and H9C2 (ATTC CRL-
1446) cells were grown in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% Fetal bovine
serum (FBS) (Lonza), 1% Penicillin/Streptomycin (Lonza),
1% Glutamine (Lonza); HVEC [25] cells were grown in RPMI
1640 supplemented as was DMEM, at 37uC, 5% CO2.
N Starvation: cells were washed twice with PBS 1X (Lonza) and
incubated with medium without FBS (starvation medium).
N Internalization assays: cells in starvation medium were
incubated at 37uC with patients’ serum or not for different
times as indicated in figures. The serum was diluted directly in
the starvation media to the final FLCs concentration of 20 mg/
mL. After serum incubation cells were washed carefully 3 times
with PBS 1X at 4uC, they were incubated with 170U of trypsin
(Lonza) 5 min at 4uC and 10 min at 37uC to remove any FLCs
remained on the cells membrane. Cells were than harvested
and centrifuged at 8006g 10 min. Pellet was re-suspended in
1 mL of PBS 1X and re-centrifuged. Cell pellets were re-
suspended in extraction buffer (100 mM Tris, 150 nM NaCl,
1 mM EDTA) supplemented with protease inhibitor cocktail
(P.I.) (32 mg/mL leupeptin, 6.4 mg/mL pepstatin, 40 mg/mL
aprotinin; Sigma). The extracts were disrupted by sonication
(Bandelin, Sonopuls) on ice for 20 seconds at 60% of
maximum power, then centrifuged at 8006 g for 10 min at
4uC (Centrifuge 5417C, Eppendorf).
Antibodies and Immunoblotting
The following antibodies were used in our experiments: sheep
anti-lambda FLC, sheep anti-kappa FLC (The Binding site),
mouse anti-clathrin heavy chain, mouse anti-LAMP-1 (BD
Transduction Laboratories), mouse anti-a-tubulin (Millipore:
Mab1637), DAPI (Invitrogen), rabbit anti c-src (Santa-Cruz),
mouse anti-Annexin V (Santa-Cruz), mouse anti-Caveolin (No-
vus). Cell pellets for western blotting were treated as described
above. The supernatants were normalized for protein concentra-
tion (Bradford Assay), boiled in reducing SDS sample buffer
(80 mM Tris, pH 6.8, 2% SDS, 7.5% glycerol, 0.01% bromo-
phenol blue) supplemented with 2% 2-mercaptoethanol (Sigma)
for 5 min at 95uC and separated by SDS–PAGE on a acrylamide/
bisacrylamide (12.5%) gel. To visualize FLCs signal we performed
electrophoresis under native conditions: samples were processed as
Table 1. Description of the patients involved in the study.
Patient Disease
K FLCs
(mg/L)
l FLCs
(mg/L) Ratio S-IF U-IF
Congo
Red IgA IgG IgM OMB
Creatinin
mg/dL
A1k AL Amyloidosis 1502 291,4 5,15 IgA/k k Pos. 48 541 35 20% plasma
cells
0,85
A2l AL Amyloidosis 27 794,5 0,03 IgG/l+
IgA/k
l Pos. 179 897 27 20% plasma
cells
2,27
M1k MM+renal failure 15000 8,04 1865 IgA/k k neg. 1970 438 10 90% plasma
cells
9,25
M2l MM+renal failure 0,12 2750 0,00 l l neg. 25 357 10 20% plasma
cells
7,2
MGUS MGUS 9,73 1180 0,01 IgG/l+l neg. \ 187 1471 89 n.a 0,7
C Healty 12,5 18,1 0,69 neg. neg. \ 253 1366 140 n.a 0,6
C Healty 7,8 14,3 0,55 neg. neg. \ 219 1140 119 n.a 0,55
S-IF: serum immunofixation; U-IF: urine immunofixation; Congo Red: periumbelical fat Congo red staining; OMB: Osteo-medullary biopsy; N.a.: not available.
doi:10.1371/journal.pone.0070811.t001
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described earlier, resuspended in non-reducing sample buffer and
boiled for 5 min at 95uC. Samples were run in a native gel (12.5%
acrylamide–bisacrylamide without SDS) and analyzed by western
blotting (WB).
Samples were transferred for 1 h onto PVDF membrane,
blocked overnight with 5% fat-free milk, 0.05% Tween-20 in PBS
1X. The PVDF membrane was incubated with the antibodies
described above for 2 h in PBS Tween 0.05% +1% fat-free milk.
The membrane was washed 36 for 10 min with PBS Tween
0.05% and incubated for 1 h with one of the following secondary
antibodies: donkey anti-sheep (Jackson Immuno Research), goat
anti-mouse and goat anti-rabbit (Zymed), sheep anti-mouse
(Amersham), goat anti-mouse Femto (Pierce), goat anti-rabbit
Femto (Pierce). Blots were detected using Supersignal West Pico or
Supersignal West Femto (Pierce) or ImmobilonWestern (Milli-
pore). Images were acquired using a G:Box Chemi XT Imaging
system (Syngene).
Microvesicles Purification and Fractionation
Microvesicles were extracted as reported previously [26,27].
Briefly, to obtain microvesicles from cells: cells in starvation
medium were incubated at 37uC with patients’ serum. The serum
was diluted in the starvation media to a final FLCs concentration
of 20 mg/mL for all samples. After 4 h of FLCs internalization,
cells were washed with PBS 1X, treated with trypsin 170 U 10 min
at 4uC and left in fresh starvation medium. After 16 h starvation
medium was collected, centrifuged at 8006g for 30 min to
eliminate cell debris, then centrifuged at 16 0006g for 45 min and
finally spun at 100 0006g for 2 h (Optima MAX Ultracentrifuge,
rotor TLA-55 Beckman), to obtain microvesicles as pellets. The
pellets were re-suspended in 25 mL PBS 1X supplemented with
P.I., clarified through a 0.1 mm filter (Millipore) to reduce the
number of contaminating large vesicles shed from the plasma
membrane and boiled with reducing or not reducing sample buffer
5 min at 95uC. The supernatant was precipitated with 10%
trichloracetic acid (TCA) (Sigma) for 6 h, centrifuged 10 min at 12
0006g, washed with CH3COONa in ethanol 20%, centrifuged
10 min at 12 0006g, re-suspended in reducing or not sample
buffer and boiled 5 min at 95uC. Samples were electrophoresed
and analysed by WB.
Alternatively, to obtain microvesicles from serum, 500 mL of
patients’ serum were processed with serial centrifugations (8006g
for 30 min, 16 0006g for 45 min, 100 0006g for 2 h) and the
pellets were re-suspended in 50 mL PBS 1X supplemented with
P.I. Reducing or not sample buffer was added and the samples
were boiled 5 min at 95uC. Samples were electrophoresed in SDS-
PAGE and native conditions and analysed by WB.
Crude microvesicle samples from patient’s serum were pro-
cessed for further fractionation using a discontinuous sucrose
gradient as previously described [28].
Samples were normalized for protein concentration (Bradford
assay) when possible, in alternative equal volumes of each sample
were loaded on a acrylamide–bisacrylamide gel.
Scanning Electron Microscopy (SEM)
Exosomes were purified from 500 mL serum with serial
centrifugations. Pellets were fixed with 2.5% glutaraldehyde
(Sigma) in PBS 1X for 1 h. After washing twice with PBS, the
fixed pellets were dehydrated with an ascending sequence of
acetone (25%, 50%, 75%, 90%, 100%). Acetone was then washed
away with high pressure liquid carbon dioxide (critical point dryer
CO2, Balzers Union). Samples were analysed by SEM after gold
sputtering (Balzers Union Sputtering System SCD 040). In
alternative serum pellets were re-suspended in 200 mL of PBS
1X and centrifuged 109 with a Cytospin4 centrifuge (The Thermo
Scientific) before CO2 dehydration and gold sputtering. All
samples were visualized on a Philips 501 SEM operating at 15 kV.
Immunofluorescences
HVEC cells were grown on glass coverslips of 35 mm of
diameter until 60–80% confluency and incubated at 37uC with
FLCs in patient’s serum (healthy patient (c), A1k, A2l, MGUS
and M1k, M2l) or only with starvation medium for 4 h. The
serum was diluted in the media to a final FLCs concentration of
20 mg/mL for all samples. Cells were fixed with 3% paraformal-
dehyde for 15 min, washed with NH4Cl for 15 min and
permeabilized with 0.3% saponin in PBS 1X 3 times 10 min.
Primary antibodies were incubated for 1 h and washed 3 times for
10 min with 0.3% saponin in PBS. Secondary antibodies were
incubated for 45 min and washed as described above. Coverslips
were mounted using an anti-fade mounting medium (ProLong
Gold-Invitrogen) on a glass slide. Fluorescent microscopy was
performed on a ZEISS Axiovert 100 microscope using the 636
Zeiss oil immersion objective. Images were processed with the use
of Image pro-plus 4.5.1.
Vesicles Quantification
After microvesicle purification from 500 mL of patients’ serum,
pellets were re-suspended in 50 mL of extraction buffer (100 mM
Tris, 150 nM NaCl, 1 mM EDTA) supplemented with P.I. and
the protein concentration was determined using the Bradford
assay.
Lipid Composition
Microvesicle pellets from 1 mL serum (c and MGUS) and
500 mL serum (M1k, M2l A1k and A2l) were re-suspended in a
total volume of 250 mL of chloroform/methanol (1:1) (v/v), and
lipids were extracted overnight at 40uC. The suspensions were
then centrifuged for 10 min at 2000 6 g, and the clear
supernatants were dried with a dryer (Reacty Vap-Pierce). The
residue was dissolved in a total volume of 100 mL chloroform/
methanol (6:4)(v/v). Each resulting solution was analysed by thin-
layer chromatography (TLC). TLC was performed in a vertical
development chamber (Camag, Muttenz, Switzerland) using 106
20 cm pre-coated TLC plates Silica Gel 60 (Merck) and a mixture
of chloroform/methanol/water (65:25:4, by volume) as mobile
Figure 1. FLCs intracellular uptake. (A) 76105 HeLa, HVEC or H9C2 cells in starvation medium were incubated with serum containing FLCs from
MM (M1k, M2l), AL amyloidosis (A1k, A2l) MGUS or healthy donor patients for 1, 2, 6 and 16 h at 37uC or not (0 h). The serum was diluted directly in
starvation media to a final FLCs concentration of 20 mg/mL for all samples. After incubation cells were processed as described in ‘‘Methods’’. Samples
were re-suspended in non-reducing SDS-free sample buffer. 30 mg of each sample were run in a native 12.5% acrylamide–bisacrylamide gel. Western
Blot (WB) analysis was performed with anti kappa, lambda FLCs and tubulin antibodies. Signals were quantified with the program Gene Tools. B)
76105 H9C2 cells in starvation medium were incubated for 2 h with serum diluted to a final concentration of 20 mg/mL of FLCs and treated as
described in Methods to visualize the differences between AL, MM, and MGUS FLCs internalization rate. Healthy donor (c) was used as negative
control. 30 mg of each sample were run in a native 12.5% acrylamide–bisacrylamide gel. WB anti FLCs and tubulin. The displayed values represent the
mean 6SEM. Each fit was performed on a minimum of 2 separate experiments. ** P,0.01.
doi:10.1371/journal.pone.0070811.g001
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phase. Lipids were visualized by spraying plates with 0.05%
primulin solution dilute with acetone:water (8:2 v/v).
Vesicles lysis
500 mL of M2l patient serum were processed for microvesicles
purification with serial ultracentrifugation steps as described in
Methods. The pellet (P1) obtained after the last ultracentrifugation
at 100 0006g for 2 h was resuspended in 100 mL of trypsin for
30 min at 37uC and then ultracentrifuged at 100 0006g for 2 h.
The pellet (P2) obtained was resuspended in 100 mL of extraction
buffer +0.1% Triton X-100 (+) or not (2) for 30 min at 4uC and
centrifuged at 100 0006g for 2 h. The pellet (P3) obtained was
resuspended in 50 mL non reducing sample buffer, sonicated at
60% of maximum power and boiled at 95uC for 5 min.
Supernatant from P3 (SN3) was precipitated by incubation with
10% trichloracetic acid (TCA) (Sigma) for 6 h, centrifuged 10 min
at 12 0006g, washed with CH3COONa in ethanol 20%,
centrifuged 10 min at 12 0006g, resuspended in 50 mL of non
reducing sample buffer and boiled 5 min at 95uC. Input (0.25 mL
total serum), P1 (2.5 mL), P3 (2.5 mL) and SN3 (2.5 mL) were
loaded on a native gel and analysed by WB using anti FLC
antibodies.
Immunocapture Assay
Magnetic beads (PureProteome NHS FlexiBind Magnetic
Beads, Millipore) were coupled with c-src or annexin V
monoclonal antibody, as described in the PureProteome Magnetic
Beads user guide. Discontinuous sucrose gradient fractions 6-7-8-9
were incubated with coupled magnetic beads over night at 4uC in
gentle rotation. The beads were then placed on a magnet and the
supernatant was discarded. The beads were washed 3 times with
PBS 1X and finally resupended in 50 mL of reducing or non
reducing sample buffer and heated at 95uC for 5 min. Samples
were run in SDS-PAGE or native conditions and analysed by WB.
Cytosol/Membrane Separation
HVEC cells in starvation medium were incubated for 4 h at
37uC with patients’ serum. The serum was diluted in the media to
a final FLCs concentration of 20 mg/mL. After serum incubation
cells were washed carefully 3 times with PBS 1X at 4uC, incubated
with 170U of trypsin (Lonza) 5 min at 4uC and 10 min at 37uC or
not. Cells were than harvested and centrifuged at 8006g for
10 min. The pellet was resuspended in extraction buffer supple-
mented with P.I., disrupted by sonication 60% of maximum power
for 10 seconds and centrifuged at 8006g for 10 min (Centrifuge
5417C, Eppendorf). The homogenate was centrifuged at 100
0006g for 1 h at 4uC (Optima MAX Ultracentrifuge, rotor TLA-
55 Beckman). The supernatant obtained was treated as cytosolic
fraction, while the pellet (membrane fraction) was re-suspended in
extraction buffer+P.I. The membrane fraction was solubilized by
sonication at 15% for 10 seconds. All samples were re-suspended
in reducing SDS sample buffer or non reducing sample buffer.
The samples were heated at 95uC for 5 min and then electro-
phoresed in SDS-PAGE or native conditions and analysed by WB.
Statistical Analysis
Significant differences among MGUS datasets and other
samples were determined with Student’s t-test (Graph Pad). P
values of less than 0.05 were considered statistically significant with
* P,0.05, ** P,0.01 and *** P,0.001. Values were shown as
mean 6 Standard Error of the mean (SEM) of at least 3
experiments.
Significant differences among MGUS datasets and other
samples in microvescicles protein content were determined with
Mann-Whitney test (Graph Pad). * P,0.05, ** P,0.01 and ***
P,0.001. Significant differences among controls (healthy donors)
datasets and patients (MM, AL and MGUS) in FLCs pelletable
fraction from serum were determined with Student’s t-test (Graph
Pad) * P,0.05, ** P,0.01 and *** P,0.001. Data represents
mean 6 Standard Error of the mean (SEM) of 2 experiments.
Results
FLCs are Internalized in Endothelial and Heart Muscle Cell
Lines
Studies show that dendritic cells, mesangial cells, kidney
epithelial cells and cardiac fibroblasts internalize both kappa and
lambda FLCs [18–20,29]. FLCs are able to disrupt the normal
physiology of organs such as the heart, peripheral nerves, lungs,
and intestines. FLCs most commonly cause disruption in the
kidney, a highly vascularized organ, both in MM and AL patients.
We chose to investigate the FLC internalization rate of endothelial
cells, cardiac myoblasts, and epithelial cells, because they serve as
good models for the environment of the organ damaged by FLCs.
Intracellular uptake and intracellular retention at different time
points were performed with different paraproteins. We chose
samples with high levels of kappa or lambda FLCs, derived from
patients with Multiple Myeloma with AL Amyloidosis (named A1k
and A2l) or without (named M1k and M2l). One MGUS patient
with an IgGl monoclonal component, in combination with
monoclonal lambda FLCs, and two healthy donors (c) were also
selected. All samples were classified for their paraprotein content
as shown in Table 1. AL amyloidosis was excluded for M1k and
M2 l since periumbilical fat was negative at Congo red staining
(Table 1).
We incubated epithelial (HeLa), endothelial (HVEC) and
cardiac (H9C2) cell lines with starvation medium containing the
same final concentration of FLCs (20 mg/mL) at different time
points. After incubation we treated the cell layers with 170U of
trypsin 5 minutes at 4uC and 10 minutes at 37uC to eliminate
FLCs that are still present on plasma membranes. This treatment
was equally efficient in eliminating residual FLCs from the cell
membranes for all tested serum samples (Figure S1A, B). Figure 1A
shows that all cell lines were able to internalize both kappa and
lambda FLCs at different time points (1 hour (h), 2 h, 6 h, 16 h)
but with significant differences: HeLa cells contained less FLCs
Figure 2. Extracellular transport of internalized FLCs. (A) 76105 HVEC cells in starvation medium were incubated with serum from M1k, M2l,
A1k, A2l, MGUS or healthy donor (c) for 4 h. Serum was diluted in starvation medium to obtain 20 mg/mL as final FLCs concentration for all samples.
The cells were then washed with PBS 1X, treated with trypsin 170 U 10 min at 4uC and left in fresh starvation medium. After 16 h, starvation medium
was collected from HVEC cells, (Microvesicles purification, Methods). Cell extracts (homogenate, H, 30 mg), supernatants (SN, 25 mL) and pellets (P,
25 mL) were run in a native gel 12.5% acrylamide–bisacrylamide gel. Western Blot were performed with anti FLCs and anti tubulin antibodies. (B)
HVEC starvation medium obtained after 16 h of chase time was centrifuged at 8006g 30 min. The supernatant was added to H9C2 cell layers in
starvation medium for 4 h. The cells were then washed with PBS 1X treated with trypsin 170 U 10 min at 4uC and left in fresh starvation medium.
After 16 h of incubation the medium from H9C2 was collected and centrifuged as described in Microvesicles purification, Methods. H, SN and P were
run in a native 12.5% acrylamide–bisacrylamide gel and analysed by WB with anti FLCs and anti tubulin antibodies.
doi:10.1371/journal.pone.0070811.g002
C-src Microvesicles in Plasma Cell Dyscrasia
PLOS ONE | www.plosone.org 6 August 2013 | Volume 8 | Issue 8 | e70811
C-src Microvesicles in Plasma Cell Dyscrasia
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e70811
than the other cell lines after 16 h of incubation. Endothelial and
myocardial cells did not reduce their FLCs content throughout
16 h and also seemed to reach a steady state level of paraprotein
uptake of both kappa and lambda FLCs. Interestingly FLCs of
patients A1k and A2l are internalized faster than M1k, M2l and
MGUS FLCs in all cell lines particularly in H9C2 cells (Figure 1B).
Myocardial cells are probably more rapid in FLCs uptake, needed
for proper paraprotein processing and heart protection, in the
presence of potential amyloidogenic proteins. Healthy patients (c),
with a normal FLCs value and kappa/lambda ratio, were used as
controls and they did not show any internalization signal in
Western blot (Figure 1A). As shown in Table 1, only the M2l
patient has a single FLCs monoclonal component. Thus to exclude
the internalization of intact immunoglobulin complexes we tested
two serum sample with a monoclonal component IgG k and IgA l
respectively, combined with normal levels of both kappa and
lambda FLCs. As shown in Figure S2 we could not see any kappa
or lambda signal under both reducing (S2A) and non reducing
(S2B) conditions, indicating that an intact immunoglobulin cannot
be internalized in cells under our experimental conditions.
FLCs are Rerouted in Extracellular Vesicles and Efficiently
Re-internalized in Contiguous Cells
Misfolded proteins are able to induce tissue damage via protein
fibrillation like the Amyloid Precursor Protein (APP) in Alzheimer
Disease. Extracellular protein moieties could be cleared by the
microglia or internalized into neurons where they might serve as
seeds to induce protein aggregation in neurodegenerative disorders
[23].
Misfolded proteins could also be transported via tunnelling
nanotubes between cells, within exosomes/microvesicles (EMVs/
MVs) or by unconventional secretion of free proteins [30].
We postulated that FLCs might behave in a similar way. Thus
we established an experimental protocol to test microvesicles
release in HVEC cells. After 4 h of FLCs internalization in
endothelial cells and 16 h chase time, cell medium has been
collected and analysed for its FLCs content. We adopted a ‘‘three
steps centrifugation’’ protocol (see ‘‘Materials and Methods’’) to
eliminate cellular debris, apoptotic membrane patches, etc… The
pellets were also filtered on a 0.1 mm mesh to confirm the potential
EMVs/MVs content. Surprisingly we could see that internalized
FLCs are redirected in the cell culture medium in a soluble (SN) or
pellettable (P) form. We postulated that the pellets are composed
by EMVs/MVs (Figure 2). In addition we could show that M1k,
M2l, A1k and A2l FLCs are efficiently delivered in both
extracellular spaces (Figure 2A, lane SN and P). M1k and M2l
FLCs are not present in the homogenate (H) after 4 h of
internalization and 16 h of chase time showing that all the FLCs
that have been internalized were rerouted in the medium and a
very little amount is retained in the cells. On the contrary, the
MGUS derived FLCs, clearly behave in a different way: the
HVEC cells homogenate (H) still contains a significant amount of
FLCs (Figure 2A first lane) and only soluble FLCs are released in
the culture medium (SN) while there are no FLCs in the pelletable
form (P). These data indicate a probably different processing way
of some FLCs. Under our experimental conditions, only malignant
plasmacells dyscrasia derived FLCs can be secreted in a pelletable
form. Cells incubated with healthy donor serum, used as negative
control, did not give any signal. To further test a prion like
spreading, as suggested in the literature for the APP [31], we
incubated myocardial cell lines (H9C2) with the endothelial cells
culture medium that holds secreted FLCs and secreted FLCs
containing vesicles (see protocol flow chart in Figure 2). We
observed an efficient intake of FLCs that where released from
endothelial cells (Figure 2B). A more efficient M1k and A2l FLCs
extracellular transport was observed in myoblasts (Figure 2B, SN
and P) after co-incubation with endothelial secreted FLC. H9C2
cells maintained the ability to secrete FLCs in the external medium
via pelletable (vesicular) structures (P) from M1k, M2l, A1k, A2l,
but not MGUS patients. Similarly, the healthy donor serum did
not give any signal. To confirm that the EMVs/MVs were
efficiently internalized, we incubated myoblasts with the pelletted
and filtered vesicles, obtained from the endothelial culture
medium, and we observed the same result (data not shown).
Internalized FLCs are Secreted in C-src, Annexin V, Hsp70
Positive Microvesicles
The detection of pellettable FLCs in the culture medium of
FLCs pre-treated cells suggested us to compare the vesicular
paraprotein release in different cell lines and with different FLCs.
As shown in Figure 3A, HeLa cells release a minimum of M1k,
M2l and MGUS derived FLCs instead of A1k and A2l, showing
an alternative way of processing. In endothelial and myocardial
cells we observed almost the opposite behaviour: plenty of M1k
and M2l FLCs are secreted in a vesicular form with minor release
of A1k and A2l and minimal release of MGUS FLCs. Cells
incubated with healthy donor serum (c) did not give any signal. All
results were estimated significant in relation to the MGUS values.
(* P,0.05, ** P,0.01 and *** P,0.001). These data indicate that
the machinery involved in FLCs processing is cellular and
paraprotein type dependent.
We then investigated the nature of microvesicles secreted in the
culture medium with different exosomal markers and c-src; c-src
has been linked to the inflammatory environment in the myeloma
kidney [21] and to the development of cancer [32]. We analysed
vesicles produced by HVEC (Figure 3B) and H9C2 (Figure 3C)
cells after FLCs internalization. As shown in Figures 3B and 3C we
observed the striking presence of the c-src tyrosine kinase on
vesicular population (P) generated in both endothelial and
myocardial cell lines incubated with M1k, M2l, A1k and A2l
sera. Furthermore in these samples we revealed the presence of
annexin V and the Heat Shock Protein (Hsp)70: two known
exosomal markers [33,34]. In addition, the secreted vesicles
harbour the Lysosomal Associated Membrane Protein 1 (Lamp-1)
and the integral membrane protein caveolin1 also known to be
present in exosomes [34,35]. In control sample (c) we saw similar
signals (Figure 3B) in the homogenate (H) but not in the pelleted
fractions (P). Under our experimental conditions in MGUS treated
Figure 3. Microvescicle characterization. (A) 76105 HeLa, HVEC or H9C2 cells in starvation medium were incubated with serum from MM (M1k,
M2l), AL amyloidosis (A1k, A2l), MGUS and healthy donor (c) patients for 4 hours at 37uC. The serum was diluted in starvation medium to a final FLCs
concentration of 20 mg/mL for all samples. Cells were then washed with PBS 1X and treated with trypsin as described in Methods and left in fresh
starvation medium for 16 h. Starvation medium was harvested, centrifuged at 8006g for 30 min, 16 0006g for 45 min and finally ultracentrifuged at
100 0006g for 2 h (see Microvesicles purification, Methods). WB analysis of cell extracts (homogenate, H, 30 mg) and pellets (P, 25 mL) were performed
with anti FLCs antibodies. Figure shows pellets quantification. Results are the mean 6SEM of at least 3 separate experiments. * P,0.05, ** P,0.01
and *** P,0.001. (B,C) HVEC and H9C2 cells were treated as described above. MGUS sample 2.86106 cells were treated as described. WB was
performed with different vesicles markers (c-src, annexinV, Hsp70, caveolin1 and Lamp1) under reducing conditions. H (Homogenate, 30 mg), P
(Pellet, 25 mL).
doi:10.1371/journal.pone.0070811.g003
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cells we observed a microvesicular population (P), caveolin1
positive, loading 4 times the amount of MM and AL treated cells.
C-src Intracellular Redistribution After Pathologic FLCs
Exposure
We saw that FLCs are internalized in HeLa, H9C2 and HVEC
cells and they are secreted in c-src positive microvescicles. Previous
studies demonstrated that c-src increases its activity in human
proximal tubular epithelial cells after urine FLC exposure,
showing their ability to generate a proinflammatory environment
[20]. Thus we analysed HVEC cells by immunofluorescence after
a 4 h incubation with or without serum from all patients (M1k
andA2l gave the same results, respectively, as did M2l and A1k,
data not shown). We observed a clear c-src intracellular re-
distribution in cells treated with serum containing FLCs. Figure 4
shows the perinuclear distribution of c-src in cells treated with
control serum (c) and untreated cells (Starv). Instead, in MGUS
and A1k treated cells, c-src shows a perinuclear distribution and a
plasma membrane clustering besides the normal perinuclear
distribution. Moreover cells treated with M2l show an active
intercellular communication, with c-src positive tunnels and
filopodia structures from cell to cell that we could never observe
in MGUS and A1k treated cells. The presence of c-src clusters at
plasma membrane in both MGUS and A1k treated cells suggests
that c-src is involved in MGUS FLCs cellular processing but not in
their vesicle delivery. It will be interesting to monitor this patient in
the next years to follow MM progression. Both c-src membrane
patches and intracellular tunnels are phalloidin positive, suggesting
that microtubules are involved in c-src redistribution. Unfortu-
nately, no commercial anti FLCs antibodies are suitable for
immunofluorescence analysis to confirm the presence of FLCs in
c-src-phalloidin positive structures. Mineo et al. recently demon-
strated that c-src signaling is activated in HUVEC after treatment
with exosomes derived from chronic myeloid leukemia cells [36].
They show that large nanotubules containing actin and tubulin
modulate exosomes internalization and secretion. These findings
support our hypothesis that FLCs exposure activate c-src
redistribution in HVEC cells from the perinuclear area to
membrane clusters and that, probably, only pathologic FLCs
(A1k and M2l), but not MGUS FLCs, are carried via
microvesicles from cell to cell.
Serum-derived Microvesicles Characterization
To verify the in vivo generation of extracellular vesicles we
collected serum samples from 72 AL Amyloidosis and MM
patients, 8 MGUS and 28 healthy donors (controls). The serum
protein profiling data for MM and AL patients are depicted in the
(Fig. S3A and Table S1). We quantified the total protein content of
the pellets obtained with a ‘‘three steps centrifugation’’ protocol
and we plotted the data with the Mann-Whitney Test. As shown in
Figure 5A serum samples from malignant plasma cell dyscrasia
(Patients) contain a significant (P,0.0001) higher amount of
pellettable proteins than MGUS and controls (c). Moreover we
could show that the serum pellet (P12) contains FLCs and that
most of FLCs are solubilised (SN3+) while few FLCs are left in the
pelletable form (P3+) after Triton-X 100 treatment (Figure S3B).
We can also conclude that FLCs are present in the inner side of
the vesicular population because of trypsin pre-treatment (P12)
(see Methods).
We analysed the lipid composition of the microvesicles/
exosomes population of M1k, M1l, A1k, A2l, and MGUS
patients and two healthy donors (c). The purified serum pellets
were loaded on a thin layer cromatography (TLC) system: all
samples contained Phosphatidylcholine (PC) and Sphingomyelin
(SFM) (Figure 5B). For the controls (c) and MGUS we loaded
twice the protein concentration of MM and AL pellets to reveal
their lipids content, further confirming that an increase of
extracellular vesicles occurs in MM and AL. To test the pellettable
amount of FLCs in serum samples we processed M1k, M2l, A1k,
A2l, MGUS and control pellets under native conditions.
Figure 5C shows that the percentage of the FLCs in the pellettable
fraction is around 2% of the FLCs present in the patients’ serum.
These results are significant (*P,0.05) compared to the FLCs
pelletable fraction of healthy donorsTo better characterize the
composition of serum pelleted material we performed morpho-
logical analyses using SEM. Figure 5D shows the presence of
vesicles with diameters from 60 to 100 nm in M1k serum patients.
The pelleted serum derived vesicles were observed as clusters of
vesicles (Figure 5D i, ii) or single vesicles (Figure 5D, iii), Similar
morphology was described for exosomes isolated from different
biological fluids [37]. The vesicles content was further character-
ized by determining the presence of Hsp 70, annexin V, tubulin
and c-src. Our data (Figure 6A) clearly show that plasma derived
microvesicles from MM (M1k and M2l) and Amyloidosis AL (A1k
and A2l) patients contain FLCs and express high levels of Hsp 70,
annexin V and c-src. Healthy donors (c) and MGUS derived
samples present exosomal associated proteins like annexin V,
Hsp70 and tubulin. However, c-src was almost absent from these
samples. These data have been confirmed for all the 8 MGUS
patients analysed (Figure 6B). To confirm that a microvesicles/
exosomes population contains FLCs, we performed a sucrose
gradient protocol. As shown in Figure 6C, fractions 7 and 8
contained the FLCs (both kappa and lambda) and are Hsp70, c-src
and annexin V positive, We show only A1k and M2l, because the
other patients (M1k and A2l) gave the same results.
Finally to confirm that FLCs are present in c-src and annexin V
positive vesicles we performed an immunocapture assay: fractions
6 to 9 from the discontinuous gradient were collected and
incubated with c-src or annexin V coupled magnetic beads. As
figure 6D shows, the c-src positive vesicles from M2l and A1k, but
not from MGUS patients and healthy donor (c), contain annexin
V and FLCs. Samples immunocaptured with anti annexin V
antibody show a FLCs signal in MGUS, M2l and A1k, but not in
the control. Moreover, c-src is visible only in M2l and A1k, but
not in MGUS and c. Thus only FLCs produced during malignant
plasma cells dyscrasia are transported via c-src and annexin V
positive EMVs/MVs.
Discussion
In the present study we demonstrated that serum FLC are
efficiently internalized in endothelial and myocardial cell lines.
Furthermore we revealed a novel mechanism for FLCs processing
Figure 4. C-src expression and distribution in HVEC cells. HVEC cells were incubated with serum of different patients (healthy patient (c), A1k,
MGUS and M2l) to a final FLCs concentration of 20 mg/mL or with starvation medium (Starv.) for 4 h at 37uC. Cells were fixed with 3% PFA,
permeabilized with 0.3% saponin and stained with the c-src antibody, followed by Alexa 488-conjugated anti-rabbit immunoglobulin (Ig), Phalloidin
555 (Alexa Fluor) and DAPI. Scale bars, 5 mm. Coverslips were mounted using an anti-fade mounting medium (ProLong Gold-Invitrogen) on a glass
slide. Confocal microscopy was performed on a ZEISS Axiovert 100 fluorescent microscope using the 636 Zeiss oil immersion objective. Single
sections are shown for each condition. Images were processed with the use of Image pro-plus 4.5.1.
doi:10.1371/journal.pone.0070811.g004
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that involves c-src labelled extracellular vesicles. Our in vitro data
are strongly confirmed by the characteristics of microvesicles
produced in vivo. More strikingly MGUS derived microvesicles are
different from those produced in MM or AL Amyloidosis,
suggesting a new prognostic tool.
Plasma cell dyscrasia is characterized by proliferation of
uncontrolled plasma cells and the accumulation of their secreted
paraproteins. Currently, patients with a malignant form (MM) of
plasma cell dyscrasia have a short life expectancy. Organs
including the lungs and heart can also be affected; if AL
Amyloidosis affects the myocardium, it could potentially cause of
morbidity.
More than one trigger factor could be involved in the prognosis
and progression of MM, including: kidney failure, AL Amyloidosis
with heart deficiency, LCDD, tubular cast nephropathy, osteolitic
lesions, peripheral neuropathy and immunodeficiency. Each
patient shows his own history and to date it is quite hard to
predict if MGUS paraproteins will be able to damage tissues.
LCDD and AL Amylodosis have been linked to different
intracellular trafficking pathways in mesangial cells: amyloidosis
light chains (AL-LCs) are delivered to the mature lysosomal
compartment where amyloid formation occurs and LCDD-LCs
alter mesangial function and phenotype [20]. To investigate the
biological effect of FLCs in the blood stream and the underlying
molecular mechanism, we analysed the processing of paraproteins
in endothelial and myocardial cells before kidney ultrafiltration.
The patient’s group we selected for endocytosis assays included
only one patient with FLC lambda Myeloma (M2l) and 4 subjects
(M1k, A1k, A2l and MGUS) with complete immunoglobulin
component associated with a FLCs component. In our preliminary
experiments we also tested two serum samples with complete
monoclonal immunoglobulin (IgGk and IgAl) with normal FLCs
values. In these experiments we could not see any FLCs
internalization signal, under non reducing conditions, in endothe-
lial and myocardial cell lines. In contrast we observed an efficient
intake of FLCs in both endothelial and myocardial cells for all
patients with in excess of FLCs. These data indicate that, under
our experimental conditions, monoclonal FLCs can be internal-
ized in myocardial and endothelial cells. The whole immunoglob-
ulin complex, if recycled through the neonatal Fc receptor, was
not detectable in the cell homogenates that we analyzed. We also
observed faster internalization rates for A1k and A2l in the two
patients with AL Amyloidosis, compared to the other patients.
Thus we confirmed a higher avidity for AL-LCs uptake in the
vascular bed, such as the one present in mesangial cells [20].
Different turnovers are probably due to disposal of proteins either
less or more toxic. Proteins could be potent messengers that
activate trafficking pathways in different cell types. Like the Ab
peptide, a component of amyloid plaques in Alzheimer disease,
paraproteins could probably trigger proinflammatory events. We
hypothesized a potential prion like propagation [38,39] from
endothelial to myocardial cell lines. The neurodegeneration has
been linked to an exosomal shipping of proteins [31]. Exosomal
release might be of advantage to cells having poor degradation
capacities: Initially, it would be beneficial to cells but later on it
would become dangerous. In order to demonstrate this hypothesis
we checked for EMVs/MVs production of human cell lines after
serum containing high amounts of FLCs exposure. Our data
showed that FLCs are redirected in the extracellular space in a
soluble form and in vesicular structures. The recent study on
urinary exosomes containing large amounts of free immunoglob-
ulin light chains, were isolated from AL Amyloidosis and MM
urine samples corroborates our findings [40]. Moreover we
observed the striking evidence that MGUS FLCs behave
differently: the internalized FLCs are transported in the culture
medium mainly in a soluble form. In addition we could show that
endothelial secreted EMVs/MVs are able to transfer their FLCs
content into myocardial cells thus suggesting a FLCs shipping
process.
Macrophage-produced MVs bind to adjacent cells, including
macrophages and dendritic cells, leading to their activation and
resulting in secretion of TNF-a and potentially other proinflam-
matory mediators [41]. Sterile inflammation can be a major factor
that triggers vascular damage and subsequent fibrosis [42].
Receptor-mediated endocytosis and metabolism of monoclonal
FLCs generates an intrarenal proinflammatory environment that
exacerbates ongoing renal injury and tubulointerstitial fibrosis in a
NF-kB mediated way [43]. It has been shown that immunoglob-
ulin FLCs activate both the canonical and atypical (IKK-
independent) NF-kB pathways through a c-src tyrosine phosphor-
ylation [21]. Our observation of c-src recruitment on microves-
icles, which contain immunoglobulin light chains, suggest a novel
mechanism of c-src activation during plasma cell dyscrasia and its
potential involvement in proinflammatory events and tissue
damage. The evidence of plasma membrane recruitment of c-src
and intercellular tunneling of c-src positive carriers after FLCs
exposure, represents a possible mechanisms linked to the
paraprotein pathogenicity.
It would be of great interest to analyse serum samples in
different MGUS patients before and after switching in malignant
plasma cell dyscrasia. The striking evidence that the MGUS
derived FLCs are unable to induce the c-src enrichment on
secreted microvesicles in vivo and in vitro requires the study of a
larger group of patients. If confirmed, the quantification of c-src
positive microvesicles could be a new diagnostic tool for the
pathogenicity prediction of paraproteins.
All these data concerning the cellular metabolism of parapro-
teins highlight the need to identify the behaviour of different serum
MVs produced by different patients. Further microvesicle and
exosomes characterization of MM versus control patients will
surely improve our knowledge at the molecular level and provide a
novel tool in diagnosing plasma cell dyscrasia patients.
Figure 5. In serum vesicles detection. (A) Microvesicles were purified from 500 mL serum of 3 different patients’ groups: Controls (28 healthy
donors), 8 MGUS, Patients (72 malignant plasma cell dyscrasia). Protein content was quantified using Bradford assay. Protocol described in ‘‘Vesicles
quantification’’ Methods. Each dot represents each sample quantification, lines are mean 6SEM. Results were analysed using Mann-Whitney test. *
P,0.05, **** P,0.0001. (B) Microvesicles lipid composition of 1 mL serum from healthy donors (c), MGUS and 500 mL serum from MM (M1k and M2l)
and AL amyloidosis (A1k and A2l) was detected with Thin Layer Chromatography (PC: phosphatidylcholine, SFM: sphingomyelin). (C) The figure
shows the percentage of the FLCs in the pellettable fraction calculated on the total amount of FLCs present in the serum (pellet vs total serum).
Results are the mean 6SEM of 2 separate experiments. * P,0.05. (D) Serum pellets obtained with serial centrifugation from M1k patients were fixed
in 2,5% glutaraldehyde, dehydrated with acetone, dried in a critical point drying device and gold coated (i 20 000X, ii 40 000 X). Pellets were re-
suspended in PBS 1X and centrifuged with a CytoSpin4 for 10 min (iii, 20 000X). Pellets were dried and processes as described above. All samples
were visualized with a Philips 501 microscope. White arrows show small vesicles of 60–100 nm in diameter.
doi:10.1371/journal.pone.0070811.g005
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Figure 6. In serum vesicles characterization. (A, B) Microvesicles purified from 500 mL serum of healthy donors (c), 8 MGUS, MM (M1K, M2l) and
AL amyloidosis (A1k, A2l) were analysed by WB with different vesicles markers. (C) Microvesicle pellets were loaded on the top of a 15–60%
discontinuous sucrose gradient. Twelve fractions of equal volume were collected from the top (low density, fraction 1) to the bottom (high density,
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Supporting Information
Figure S1 Trypsin treatment, after internalization,
efficiently eliminates all type of residual FLCs from cell
membrane. (A) HVEC cells in starvation medium were
incubated with serum containing FLCs from M2l patient for
4 h at 37uC. The serum was diluted directly in starvation medium
to a final FLCs concentration of 20 mg/mL. After incubation cells
were washed carefully at 4uC with PBS 1X, incubated 5 min at
4uC and 10 min at 37uC with 170 U trypsin (+) or not (2). Cells
were processed as described in ‘‘Cytosol/membrane separation’’
(Methods) (H, homogenate; cyt, cytosol; mb, membrane). 30 ug of
each sample were loaded on a SDS–PAGE or native gel and
analysed by WB anti FLCs and flotilin, the last used as a
membrane marker. (B) HVEC cells were incubated with serum
containing FLCs from MM (M1k, M2l), AL amyloidosis (A1K,
A2l), MGUS or healthy donor (c) for 4 h. Serum was diluted to
obtain 20 mg/mL as final FLCs concentration for all samples.
Cells were then treated with trypsin (+), as described above, and
processed for the Cytosol/membrane separation (H, homogenate;
mb, membrane). 30 ug of each sample were loaded on a SDS-
PAGE or a native gel and analysed as described.
(TIF)
Figure S2 Denaturing or native electrophoresis analysis
of internalized FLCs. (A) HVEC cells in starvation medium
were incubated with serum containing FLCs from AL amyloidosis
(A1k, A2l), two patients with monoclonal component but normal
FLCs levels (IgGk and IgAl) or healthy donor patients (c) for 4 h
at 37uC. The serum was diluted in starvation media to a final
FLCs concentration of 20 mg/mL for all samples. After incubation
cells were washed carefully at 4uC with PBS 1X, incubated 5 min
at 4uC and 10 min at 37uC with 170 U of trypsin to remove any
FLCs attached to cell membrane and processed as described in ‘‘
Internalization assay’’ (Methods). Samples were resuspended in
SDS sample buffer. 30 mg of each sample were run in SDS-PAGE,
12.5% acrylamide–bisacrylamide gel. B) HVEC cells were
processed as reported above and the samples were resuspended
in non-reducing SDS-free sample buffer. 30 mg of each sample
were run in a native 12.5% acrylamide–bisacrylamide gel.
Western Blot (WB) analysis was performed with anti kappa, anti
lambda FLCs and anti tubulin antibodies
(TIF)
Figure S3 Characterization of patients’ sera. (A) Percent-
age of monoclonal component isotypes:. each column represent
the percentage of patients producing the same monoclonal
component isotype. ‘‘Others’’, is a smaller group with: double
IgGk, k, l, IgAl+ IgGk, IgGk+l, IgMk, IgMk+IgMl,
IgMl+IgGk. The mean value of kappa and lambda FLCs
concentrations in all patients is also shown. B) 500 mL of M2l
patient serum were processed for microvesicles purification with
serial ultracentrifugation steps as described in Methods (Vesicles
lysis) and processed with Triton-X 100 to confirm that FLCs were
in the vesicles. WB was performed with anti lambda FLCs
antibodies. Figure shows that the untreated serum pellet (P1)
contained FLCs, but after Trypsin,Triton-X 100 treatment, and
centrifugation, the majority of FLCs were in the supernatant
(SN3+) and not in the pellettable form (P3+) (Figure S3B).
(TIF)
Table S1 Characterization of the monoclonal compo-
nents of all patients involved in this study. The table
shows: serum immunofixation (IF-S) and urine immunofixation
(IF-U) results; kappa and lambda FLCs serum concentration and
ratio; immunoglobulin quantification (IgA- IgG- IgM). N.a.: not
available.
(DOCX)
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